August 20, 2020

Journal Club Premieres with Therapeutic Pipeline

Episode 88

A discussion with dermatologists Dr. Mark Lebwohl and Dr. Andrew Blauvelt.

Join us for our new Psound Bytes Journal Club series discussing noteworthy publications in psoriatic disease. In this first episode, we discuss three recent trial results for therapeutics in the pipeline with dermatologists Dr. Mark Lebwohl, Professor and Chairman Dept. of Dermatology, Icahn School of Medicine, Mt Sinai Health System in New York, and Dr. Andrew Blauvelt, President, Oregon Medical Research Center in Portland, OR.



TyK2 Inhibitor


Related Items

Stay in the Know

Expert tips, can’t-miss events, and the latest news, straight to your inbox.

National Health Council Standards of ExcellenceCharity NavigatorCommunity Health Charities logo

Copyright © 1996-2023 National Psoriasis Foundation/USA

Duplication, rebroadcast, republication, or other use of content appearing on this website is prohibited without written permission of the National Psoriasis Foundation (NPF).

NPF does not endorse or accept any responsibility for the content of external websites.

NPF does not endorse any specific treatments or medications for psoriasis and psoriatic arthritis.

We use cookies to offer you a better experience and analyze our site traffic. By continuing to use this website, you consent to the use of cookies in accordance with our Privacy Policy.